Premium
Erucin and Benzyl Isothiocyanate Suppress Growth of Late Stage Primary Human Ovarian Carcinoma Cells and Telomerase Activity In Vitro
Author(s) -
Lamy Evelyn,
Oey Dewi,
Eißmann Florian,
Herz Corinna,
Münstedt Karsten,
Tinneberg HansRudolf,
MerschSundermann Volker
Publication year - 2013
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.4798
Subject(s) - telomerase , apoptosis , dna fragmentation , programmed cell death , ovarian carcinoma , cancer research , viability assay , biology , cytotoxic t cell , cell growth , cytotoxicity , cell culture , ovarian cancer , chemistry , microbiology and biotechnology , in vitro , medicine , cancer , biochemistry , genetics , gene
In the present study we analysed the effects of isothiocyanates (ITCs) ‐ plant‐derived sulphur‐containing constituents known for their potential chemotherapeutic activity ‐ on growth inhibition and programmed death in primary ovarian carcinoma cells from ascites of human patients. Twenty‐four hour exposure of carcinoma cells to 5–50 μM erucin or benzyl ITC led to a concentration‐dependent viability loss, as determined by erytrosin B cell staining. This concurred with an increase in internucleosomal DNA fragmentation, mitochondrial membrane depolarization and downregulation of Akt as indicator for apoptosis induction. Cell accumulation at the G2/M phase was evident after 48 h of erucin treatment. Telomerase, a selective target of cancer cells, was suppressed by erucin. Although pre‐treatment of cells with the thiol antioxidant N‐acetylcysteine could completely prevent initialization of the apoptotic process, it failed to abolish ITC‐mediated telomerase suppression. Taken together, in our study, ITC exerted comparable cytotoxic efficacy against primary ovarian cancer cells as reported for corresponding cell lines. The clinical significance of this observation should be addressed in future studies and the role of telomerase further investigated. Copyright © 2012 John Wiley & Sons, Ltd.